Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: A focus on neuropsychiatric adverse events

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 3, 2002, Pages 294-301

  Van Riemsdijk, M M ^a,b,c   Sturkenboom, M G J M ^a,b,c   Ditters, J M ^a,b,c   Ligthelm, R J ^a,b,c   Overbosch, D ^a,b,c   Stricker, B H Ch ^a,b,c,d  

^a Havenziekenhuis   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Drug Safety Unit   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; MEFLOQUINE; PLACEBO; PROGUANIL;

ACCURACY; ADULT; AFFECTIVE NEUROSIS; AGE; AGED; ARTICLE; ATTENTION; CLINICAL TRIAL; CODING; COGNITION; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG USE; ENDEMIC DISEASE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALE; MOOD; NETHERLANDS; NEUROPSYCHIATRY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SCREENING; TIME; TRAVEL; VISUOMOTOR COORDINATION;

ADOLESCENT; ADULT; AFFECT; ANTIMALARIALS; ATOVAQUONE; CHI-SQUARE DISTRIBUTION; CHLOROGUANIDE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALARIA; MALE; MEFLOQUINE; NAPHTHOQUINONES; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 0036736525     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.127113     Document Type: Article

References (27)

1. Malaria, the submerged disease
2. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: A randomised, double-blind study
3. Atovaquone-proguanil versus mefloquine in nonimmune travellers: Results from a randomized, double-blind study
4. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80)
5. Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro
6. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite
7. Proguanil (hydrochloride)
8. Atovaquone and proguanil hydrochloride for prophylaxis of malaria
9. Central role of hemoglobin degradation in mechanisms of action of 4- aminoquinolines, quinoline methanols, and phenanthrene methanols
10. Malaria
11. Diagnosis, treatment, and prevention of malaria
12. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa
13. Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy
14. Prevention of malaria
15. De verkorte versie van de Nederlandse vertaling van de Profile of Mood States (POMS)
16. Use of computerized test batteries for quantifying neurobehavioral outcomes
17. Mefloquine prophylaxis: An overview of spontaneous reports of severe psychiatric reactions and convulsions
18. Mefloquine to prevent malaria: A systematic review of trials
19. Neuropsychiatric side effects of mefloquine
20. Neuropsychiatric side effects after the use of mefloquine
21. Mefloquine tolerability during chemoprophylaxis: Focus on adverse event assessments, stereochemistry and compliance
22. Tolerance of mefloquine by SwissAir trainee pilots
23. Neuropsychiatric effects of antimalarials
24. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: Postal and telephone survey of travellers